Which Pathway
Fits Your Product
Choose the right route based on your
development goal.
505(b)(1)
Choose 505(b)(1) if you are developing a novel drug with a new active ingredient and need full evidence of safety and efficacy.
505(b)(2)
Choose 505(b)(2) if you want to improve an existing approved drug (new formulation, dosage form, indication, or route) while leveraging existing FDA data to reduce time and cost.
505(j)
Choose ANDA (505(j)) if your objective is to develop a generic equivalent that matches the reference listed drug in quality and performance.
FDA Approval Paths
|
Parameter |
505(b)(1) – NDA |
505(b)(2) – Hybrid NDA |
ANDA (505(j)) |
|
Primary Objective |
Approval for a completely new drug with a new active ingredient. |
Approval for a modified/improved version of an approved drug. |
Approval for a generic version of an approved Reference Listed Drug (RLD). |
|
Type of Product |
Novel drug |
Improved/Reformulated drug |
Generic drug |
|
API |
New API |
Existing API with modifications |
Same API as RLD |
|
Reliance on Existing FDA Data |
No |
Partial |
Complete |
|
Clinical Studies |
Full preclinical + Phase I–III |
Only additional studies required |
No efficacy studies; BE study required |
|
Preclinical Studies |
Required |
If needed |
Generally not required |
|
Bioequivalence |
Usually not required |
May be required |
Mandatory |
|
Safety & Efficacy Data |
Generated by sponsor |
Sponsor + FDA findings |
Relies on RLD |
|
Timeline |
10–15 years |
2–5 years |
1–3 years |
|
Development Cost |
Very High |
Moderate |
Low |
|
Regulatory Complexity |
Highest |
Moderate |
Lower |
|
Innovation |
High |
Moderate |
Minimal |
|
Exclusivity |
5 years NCE or applicable |
Up to 3 years if eligible |
Generally none (except 180-day first generic) |
|
Patent Opportunity |
High |
Moderate |
Limited |
|
Risk |
High |
Moderate |
Low |
Key Takeaway
The success of a pharmaceutical product begins with selecting the right regulatory pathway. Whether developing a novel therapy, enhancing an existing medicine, or introducing an affordable generic, choosing the appropriate FDA pathway enables efficient development, optimized investment, and improved patient access.
